Monday, August 10, 2020 8:29:15 AM
Let's reiterate the important facts and opinions about VXRT. Reported by American Council on Science and Health, " a norovirus vaccine - there isn't one at this time - would be a welcome tool to combat a common ( 20 million/year cases in the US). A highly infectious, extremely unpleasant infection. A report has recently been made public in Canada had a recall recently. https://nationalpost.com/news/canada/public-health-agency-of-canada-says-more-illnesses-linked-to-u-s-grown-onions This is a form of norovirus disease. (gastroenteritis) Salmonella contamination. 685 million people catch it yearly worldwide. https://www.thesun.co.uk/news/10450353/norovirus-kills-every-year-protect-family/
GII.4 is in clinical progress with VXRT.
Reported by US National Library of Medicine: "With approximately 20% of all gastroenteritis cases and 200,000 deaths occurring per year primarily due to complications from dehydration and malnutrition, human norovirus-associated infections are a major disease and economic burden, costing 60 billion USD in health care costs and loss of societal productivity globally."
GII.4 is in clinical progress with VXRT.
Reported by US National Library of Medicine: "With approximately 20% of all gastroenteritis cases and 200,000 deaths occurring per year primarily due to complications from dehydration and malnutrition, human norovirus-associated infections are a major disease and economic burden, costing 60 billion USD in health care costs and loss of societal productivity globally."
Recent VXRT News
- Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders • GlobeNewswire Inc. • 05/19/2026 08:01:00 PM
- Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/07/2026 08:05:00 PM
- Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET • GlobeNewswire Inc. • 05/01/2026 12:00:00 PM
- Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors • GlobeNewswire Inc. • 04/23/2026 08:30:00 PM
- Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital • GlobeNewswire Inc. • 04/17/2026 12:30:00 PM
- Vaxart Provides Business Update and Reports Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/12/2026 08:05:00 PM
- Vaxart to Host Upcoming Conference Calls • GlobeNewswire Inc. • 03/03/2026 09:01:00 PM
- Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 • GlobeNewswire Inc. • 02/18/2026 01:00:00 PM
- Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants • GlobeNewswire Inc. • 01/15/2026 01:00:00 PM
- Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026 • GlobeNewswire Inc. • 01/08/2026 09:01:00 PM
- Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/13/2025 09:05:00 PM
- Vaxart to Host Upcoming Conference Calls • GlobeNewswire Inc. • 11/07/2025 01:00:00 PM
- Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025 • GlobeNewswire Inc. • 10/20/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/10/2025 09:00:20 PM
- Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025 • GlobeNewswire Inc. • 10/08/2025 12:00:00 PM
- Vaxart Announces Withdrawal of Reverse Stock Split Proposal • GlobeNewswire Inc. • 09/19/2025 12:00:00 PM
- Concerned Vaxart Stockholders Respond to Inadequate Governance Announcements • GlobeNewswire Inc. • 09/18/2025 01:00:00 PM
- Vaxart Appoints W. Mark Watson as Lead Independent Director • GlobeNewswire Inc. • 09/17/2025 08:05:01 PM
- Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate • GlobeNewswire Inc. • 09/10/2025 08:54:58 PM
- Form PX14A6G - Notice of exempt solicitation submitted by non-management • Edgar (US Regulatory) • 09/10/2025 03:00:26 PM
- Concerned Vaxart Stockholders Condemn Board’s Decision to Adjourn Reverse Stock Split Vote at Special Meeting • GlobeNewswire Inc. • 09/10/2025 01:00:58 PM
- Vaxart Announces Adjournment of Special Meeting of Stockholders • GlobeNewswire Inc. • 09/08/2025 12:00:00 PM
- Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025 • GlobeNewswire Inc. • 09/03/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/02/2025 09:09:34 PM
- Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors • GlobeNewswire Inc. • 09/02/2025 08:30:52 PM
